{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:50:45Z","timestamp":1793742645529,"version":"4.6.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.annonc.2021.03.005","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T09:36:44Z","timestamp":1616060204000},"page":"746-756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":404,"title":["Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial"],"prefix":"10.1016","volume":"32","author":[{"given":"A.","family":"Bardia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.A.","family":"Messersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Kio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vahdat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Moroose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Picozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"O'Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Starodub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Sharkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Maliakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.A.","family":"Wegener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Ocean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2021.03.005_bib1","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.3802\/jgo.2019.30.e56","article-title":"Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer","volume":"30","author":"Normann","year":"2019","journal-title":"J\u00a0Gynecol Oncol"},{"key":"10.1016\/j.annonc.2021.03.005_bib2","first-page":"e117","article-title":"Third- or later-line therapy for metastatic colorectal cancer: reviewing best practice","volume":"18","author":"Bekaii-Saab","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.annonc.2021.03.005_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4137\/BCBCR.S32783","article-title":"A\u00a0review of systemic treatment in metastatic triple-negative breast cancer","volume":"10","author":"Zeichner","year":"2016","journal-title":"Breast Cancer (Auckl)"},{"issue":"suppl 6","key":"10.1016\/j.annonc.2021.03.005_bib4","doi-asserted-by":"crossref","first-page":"vi46","DOI":"10.1093\/annonc\/mds195","article-title":"Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents","volume":"23","author":"Andre","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.03.005_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/cco.2018.05.01","article-title":"Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable?","volume":"7","author":"Hattori","year":"2018","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.005_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40661-017-0056-7","article-title":"New therapies for advanced, recurrent, and metastatic endometrial cancers","volume":"4","author":"Makker","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1016\/j.annonc.2021.03.005_bib7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14712598.2020.1757067","article-title":"Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy","volume":"20","author":"Goldenberg","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.annonc.2021.03.005_bib8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2021.03.005_bib9","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.03.005_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/ph13090245","article-title":"Antibody-drug conjugates: the last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.annonc.2021.03.005_bib11","series-title":"Kadcyla [package insert]","year":"2019"},{"key":"10.1016\/j.annonc.2021.03.005_bib12","series-title":"Mylotarg [package insert]","year":"2018"},{"key":"10.1016\/j.annonc.2021.03.005_bib13","series-title":"Enhertu [package insert]","year":"2019"},{"key":"10.1016\/j.annonc.2021.03.005_bib14","series-title":"Padcev [package insert]","year":"2019"},{"key":"10.1016\/j.annonc.2021.03.005_bib15","series-title":"Besponsa [package insert]","year":"2017"},{"key":"10.1016\/j.annonc.2021.03.005_bib16","series-title":"Lumoxiti [package insert]","year":"2018"},{"key":"10.1016\/j.annonc.2021.03.005_bib17","series-title":"Polivy [package insert]","year":"2019"},{"key":"10.1016\/j.annonc.2021.03.005_bib18","series-title":"Adcetris [package insert]","year":"2019"},{"key":"10.1016\/j.annonc.2021.03.005_bib19","series-title":"Trodelvy [package insert]","year":"2020"},{"key":"10.1016\/j.annonc.2021.03.005_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920915980","article-title":"Novel antibody-drug conjugates for triple negative breast cancer","volume":"12","author":"Nagayama","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.annonc.2021.03.005_bib21","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.3390\/cancers12113225","article-title":"Advances in acute myeloid leukemia: recently approved therapies and drugs in development","volume":"12","author":"Stanchina","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2021.03.005_bib22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7","article-title":"Human Trop-2 is a tumor-associated calcium signal transducer","volume":"76","author":"Ripani","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annonc.2021.03.005_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 quantitatively stimulates human cancer growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.annonc.2021.03.005_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1472-6890-12-22","article-title":"Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma","volume":"12","author":"Bignotti","year":"2012","journal-title":"BMC Clin Pathol"},{"key":"10.1016\/j.annonc.2021.03.005_bib25","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.annonc.2021.03.005_bib26","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2021.03.005_bib27","series-title":"Cytotoxic Payloads for Antibody-Drug Conjugates","first-page":"166","article-title":"Topoisomerase inhibitors as antibody-drug conjugate payloads","author":"Govindan","year":"2019"},{"key":"10.1016\/j.annonc.2021.03.005_bib28","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2021.03.005_bib29","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.03.005_bib30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.annonc.2021.03.005_bib31","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.03.005_bib32","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.03.005_bib33","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1158\/1535-7163.MCT-12-1170","article-title":"Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers","volume":"12","author":"Govindan","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2021.03.005_bib34","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2021.03.005_bib35","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.005_bib36","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","article-title":"Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan","volume":"23","author":"Gray","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.03.005_bib37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.2019.37.7_suppl.354","article-title":"Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): results from a phase I\/II study","volume":"37","author":"Tagawa","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.005_bib38","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","article-title":"Sacituzumab govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial","volume":"31","author":"Kalinsky","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.03.005_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2021.03.005_bib41","unstructured":"Tang W, Huang X, Ou Z, et\u00a0al. BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of Trop-2 positive triple negative breast cancer [poster]. Presented at the Annual Meeting for the CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX;\u00a02018."},{"key":"10.1016\/j.annonc.2021.03.005_bib42","doi-asserted-by":"crossref","first-page":"9619","DOI":"10.1200\/JCO.2020.38.15_suppl.9619","article-title":"Dose escalation and expansion from the phase 1 study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate, in patients with advanced non-small cell lung cancer","volume":"38","author":"Lisberg","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.005_bib43","series-title":"Camptosar [package insert]","year":"2020"},{"key":"10.1016\/j.annonc.2021.03.005_bib44","article-title":"Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer [poster]","author":"Rugo","year":"2020","journal-title":"Presented at the San Antonio Breast Cancer Symposium,"},{"key":"10.1016\/j.annonc.2021.03.005_bib45","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.005_bib46","doi-asserted-by":"crossref","first-page":"560","DOI":"10.18632\/oncotarget.27342","article-title":"Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas","volume":"11","author":"Lopez","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2021.03.005_bib47","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1878-0261.12627","article-title":"Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in\u00a0vitro and in\u00a0vivo","volume":"14","author":"Perrone","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.annonc.2021.03.005_bib48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ygyno.2019.11.018","article-title":"In\u00a0vitro and in\u00a0vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma","volume":"156","author":"Han","year":"2020","journal-title":"Gynecol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421008838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421008838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:02:05Z","timestamp":1760335325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421008838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0923753421008838"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.03.005","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}